Maren H. Harms

Maren H. Harms

Auto-generated profile, based on publicly available information

Maren H. Harms

Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
WLWillem J. Lammers
Willem J. Lammers
GHGideon M. Hirschfield
Gideon M. Hirschfield
CCChristophe Corpechot
Christophe Corpechot
FNFrederik Nevens
Frederik Nevens
KLKeith D. Lindor
Keith D. Lindor
HBHenk R. van Buuren
Henk R. van Buuren

1 August 2019 in Journal of Hepatology
Verified
Journal Article
Closed access
MHMaren H. Harms
Maren H. Harms
HBHenk R. van Buuren
Henk R. van Buuren
CCChristophe Corpechot
Christophe Corpechot
DTDouglas Thorburn
Douglas Thorburn
HJHarry L.A. Janssen
Harry L.A. Janssen
Adriaan J. van der MeerAdriaan J. van der Meer
Adriaan J. van der Meer

1 January 2019 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
Aldo J. Montano-LozaAldo J. Montano-Loza
Aldo J. Montano-Loza
BHBettina Hansen
Bettina Hansen
CCChristophe Corpechot
Christophe Corpechot
DRDavide Roccarina
Davide Roccarina
DTDouglas Thorburn
Douglas Thorburn
AMAndrew Mason
Andrew Mason

23 November 2016 in Hepatology
Verified
Journal Article
Open access
PDF file
EVElisabeth M. G. de Vries
Elisabeth M. G. de Vries
MKManon de Krijger
Manon de Krijger
MFMartti Färkkilä
Martti Färkkilä
JAJohanna Arola
Johanna Arola
PSPeter Schirmacher
Peter Schirmacher
CPCyriel Y. Ponsioen
Cyriel Y. Ponsioen
Histologic scoring systems specific for primary sclerosing cholangitis (PSC) are not validated. We recently determined the applicability and prognostic value of three histological scoring systems in a single PSC cohort. The aim of this study was to validate their prognostic use and reproducibility across a multicenter PSC cohort. Liver biopsies from PSC patients were collected from seven European institutions. Histologic scoring was performed using the Nakanuma, Ishak, and Ludwig scoring systems. Biopsies were independently scored by six liver pathologists for interobserver agreement. The prognostic value of clinical, biochemical, and all three histologic scoring systems on predicting composite endpoints 1 (PSC‐related death and liver transplantation), 2 (liver transplantation), and 3 (liver‐related events), was assessed using univariable and multivariable Cox proportional hazards modeling. A total of 119 PSC patients were identified, and the median follow‐up was 142 months. During follow‐up, 31 patients died (20 PSC‐related deaths), 31 patients underwent liver transplantation, and 35 patients experienced one or more liver‐related events. All three staging systems were independent predictors of endpoints 2 and 3 (Nakanuma system: hazard ratio [HR], 3.16 [95% confidence interval (CI), 1.49‐6.68] for endpoint 2 and HR, 2.05 [95% CI, 1.17‐3.57] for endpoint 3; Ishak system: HR, 1.55 [95% CI, 1.10‐2.18] for endpoint 2 and HR, 1.43 [95% CI, 1.10‐1.85] for endpoint 3; Ludwig system: HR, 2.62 [95% CI, 1.19‐5.80] for endpoint 2 and HR, 2.06 [95% CI, 1.09‐3.89] for endpoint 3). Only the Nakanuma staging system was independently associated with endpoint 1: HR, 2.14 (95% CI, 1.22‐3.77). Interobserver agreement was moderate for Nakanuma stage (κ = 0.56) and substantial for Nakanuma component fibrosis (κ = 0.67), Ishak stage (κ = 0.64), and Ludwig stage (κ = 0.62). Conclusion: We confirm the independent prognostic value and demonstrate for the first time the reproducibility of staging disease progression in PSC using the Nakanuma, Ishak, and Ludwig staging systems. The Nakanuma staging system—incorporating features of chronic biliary disease—again showed the strongest predictive value. (Hepatology 2017;65:907‐919).

1 February 2018 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
MHMaren H Harms
Maren H Harms
WLWillem J Lammers
Willem J Lammers
DTDouglas Thorburn
Douglas Thorburn
CCChristophe Corpechot
Christophe Corpechot
PIPietro Invernizzi
Pietro Invernizzi
HBHenk R van Buuren
Henk R van Buuren
In this era of near universal ursodeoxycholic acid (UDCA) treatment for primary biliary cholangitis (PBC), progression to cirrhosis still occurs in an important proportion of patients. The aim of this study was to describe the incidence of cirrhosis-associated complications in patients with PBC and assess risk factors and impact on survival. Cohorts of UDCA-treated patients from 16 European and North-American liver centers were included. We used Cox proportional hazards assumptions and Kaplan–Meier estimates. During 8.1 years’ median follow-up, 278 of 3,224 patients developed ascites, variceal bleeding, and/or encephalopathy (incidence rate of 9.7 cases/1,000 patient years). The overall cumulative incidence was 9.1% after 10 years of follow-up, but decreased over time to 5.8% after the year 2000. Earlier calendar year of diagnosis (P<0.001), high aspartate aminotransferase to platelets ratio index (APRI; P<0.001) and biochemical non-response (P0.54 after 12 months of UDCA had a 10-year complication rate of 37.4%, as compared to 3.2% in biochemical responders with an APRI ≤0.54. The 10-year transplantation-free survival after a complication was 9% (time-dependent hazard ratio 21.5; 20.1–22.8). Prognosis after variceal bleeding has improved over time. In this large international cohort, up to 15% of UDCA-treated PBC patients developed major non-neoplastic, cirrhosis-associated hepatic complications within 15 years, but cumulative incidence has decreased over time. Biochemical non-response to UDCA and APRI were independent risk factors for these complications. Subsequent long-term outcome after complications is generally poor, but has improved over the past decades.

18 December 2018 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
MHMaren H. Harms
Maren H. Harms
QJQuisette P. Janssen
Quisette P. Janssen
RARene Adam
Rene Adam
CDChristophe Duvoux
Christophe Duvoux
DMDarius Mirza
Darius Mirza
T(the European Liver and Intestine Transplant Association (ELITA)
the European Liver and Intestine Transplant Association (ELITA)
Summary: Background: The importance of primary biliary cholangitis as an indication for liver transplantation has probably been influenced by the introduction of therapies, and changes in selection criteria and disease epidemiology.Aims: To assess the time trends in liver transplantation for primary biliary cholangitis and to evaluate the characteristics of the patient population during the past three decades.Methods: Patients undergoing liver transplantation from 1986 to 2015 in centres reporting to the European Liver Transplantation Registry were included. We excluded combined organ transplantations and patients <18 years. Trends were assessed using linear regression models.Results: We included 112 874 patients, of whom 6029 (5.3%) had primary biliary cholangitis. After an initial increase in the first decade, the annual number of liver transplantation for primary biliary cholangitis remained stable at around 200. The proportion of liver transplantations for primary biliary cholangitis decreased from 20% in 1986 to 4% in 2015 (P < 0.001). Primary biliary cholangitis was the only indication showing a consistent proportional decrease throughout all decades. From the first to the third decade, the age at liver transplantation increased from 54 (IQR 47‐59) to 56 years (IQR 48‐62) and the proportion of males increased from 11% to 15% (both P < 0.001).Conclusions: We have found a proportional decrease in primary biliary cholangitis as indication for liver transplantation. However, despite treatment with ursodeoxycholic acid and improved disease awareness, the absolute annual number of liver transplantations has stabilised.